Article

HGF receptor up-regulation contributes to the angiogenic phenotype of human endothelial cells and promotes angiogenesis in vitro

Institut des Vaisseaux et du Sang, Centre de Recherche de l'Association Claude Bernard, Paris, France.
Blood (Impact Factor: 9.78). 07/2003; 101(12):4816-22. DOI: 10.1182/blood-2002-06-1731
Source: PubMed

ABSTRACT Hepatocyte growth factor (HGF) is a mesenchyme-derived pleiotropic growth factor and a powerful stimulator of angiogenesis, which acts on cells by binding to the c-met receptor. The exact role of the endogenous HGF/c-met system in one or more steps of the angiogenic process is not completely understood. To contribute to this question we used immunocytochemical analysis, Western blotting, and reverse transcription-polymerase chain reaction to study the expression of c-met in endothelial cells cultured in different growth conditions. We found that c-met is not colocalized with vascular endothelial (VE)-cadherin in cell-cell junctions. c-met and VE-cadherin were shown to be inversely regulated by cell density, at both the protein and the mRNA levels. We established that c-met is up-regulated during the in vitro recapitulation of several steps of angiogenesis. The c-met expression was increased shortly after switching to angiogenic growth conditions and remained high during the very first steps of angiogenesis, including cell migration, and cell proliferation. The endothelial cells in which the expression of c-met was up-regulated were more responsive to HGF and exhibited a higher rate of morphogenesis. Moreover, the antibody directed against the extracellular domain of the c-met inhibited angiogenesis in vitro. Our results suggest that c-met is a marker of angiogenic phenotype for endothelial cells and represents an attractive target for the development of new antiangiogenic therapies.

0 Followers
 · 
68 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: To investigate the angiogenic role of the HGF/cMET pathway and its inhibition in bone marrow (BM) endothelial cells (ECs) from patients with multiple myeloma (MM) vs those with monoclonal gammopathy of undetermined significance (MGUS) or benign anemia (controls). Experimental Design: The HGF/cMET pathway was evaluated in ECs from MM patients (MMECs) at diagnosis, at relapse after bortezomib- or lenalidomide-based therapies or on refractory phase to these drugs, in ECs from patients with MGUS (MGECs), and in those from controls. The effects of a selective cMET tyrosine kinase inhibitor (SU11274) on the MMECs angiogenic activities were studied in vitro and in vivo. Results: MMECs express more HGF, cMET, and activated cMET (phospho (p)-cMET) at both RNA and protein level vs MGECs and control ECs. MMECs are able to maintain the HGF/cMET pathway activation in absence of external stimulation, while treatment with anti-HGF and anti-cMET neutralizing antibodies (Abs) is able to inhibit the cMET activation. The cMET pathway regulates several MMECs activities including chemotaxis, motility, adhesion, spreading, and whole angiogenesis. Its inhibition by SU11274 impairs these activities in a statistically significant fashion when combined with bortezomib or lenalidomide, both in vitro and in vivo. Conclusions: An autocrine HGF/cMET loop sustains MM angiogenesis, and represents an appealing new target to potentiate the antiangiogenic management of MM patients.
    Clinical Cancer Research 09/2014; DOI:10.1158/1078-0432.CCR-14-0847 · 8.19 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hepatocyte growth factor (HGF) and its tyrosine kinase receptor (Met) play important roles in myocardial function both in physiological and pathological situations. In the developing heart, HGF influences cardiomyocyte proliferation and differentiation. In the adult, HGF/Met signaling controls heart homeostasis and prevents oxidative stress in normal cardiomyocytes. Thus, the possible cardiotoxicity of current Met-targeted anti-cancer therapies has to be taken in consideration. In the injured heart, HGF plays important roles in cardioprotection by promoting: (1) prosurvival (anti-apoptotic and anti-autophagic) effects in cardiomyocytes, (2) angiogenesis, (3) inhibition of fibrosis, (4) anti-inflammatory and immunomodulatory signals, and (5) regeneration through activation of cardiac stem cells. Furthermore, we discuss the putative role of elevated HGF as prognostic marker of severity in patients with cardiac diseases. Finally, we examine the potential of HGF-based molecules as new therapeutic tools for the treatment of cardiac diseases.
    10/2014; 2(4):247-262. DOI:10.3390/biomedicines2040247
  • [Show abstract] [Hide abstract]
    ABSTRACT: In the last decade, the tyrosine kinase receptor cMET, together with its ligand hepatocyte growth factor (HGF), has become a target in non-small cell lung cancer (NSCLC). Signalization via cMET stimulates several oncological processes amongst which are cell motility, invasion and metastasis. It also confers resistance against several currently used targeted therapies, e.g., epidermal growth factor receptor (EGFR) inhibitors. In this review, we will discuss the basic structure of cMET and the most important signaling pathways. We will also look into aberrations in the signaling and the effects thereof in cancer growth, with the focus on NSCLC. Finally, we will discuss the role of cMET as resistance mechanism.
    03/2015; 7(2):556-573. DOI:10.3390/cancers7020556

Preview